Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 314 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infiltration Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Testing the Anesthetic Effectiveness of Buffered Articaine Injected Next to a Lower First Molar.

NCT01862614
View directory record Official record
Conditions
Anesthetic Effectiveness
Interventions
Articaine Hydrochloride + Epinephrine, Buffered Articaine Hydrochloride + Epinephrine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Not applicable Interventional Results available

Radiographic Progression of Infiltrated Caries Lesions In-vivo

NCT01496456
View directory record Official record
Conditions
Dental Caries
Interventions
Resin infiltration, Caries management
Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 23, 2026, 8:25 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

NCT03807973
View directory record Official record
Conditions
Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
Interventions
[Zr-89]Oxine-labeled leukocytes PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Nebulized Albuterol on Donor Oxygenation

NCT00310401
View directory record Official record
Conditions
Brain Death, Organ Donor, Pulmonary Edema
Interventions
Albuterol, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
14 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Phase 3 Interventional Results available

Intranasal Fentanyl as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage

NCT03872700
View directory record Official record
Conditions
Abscess
Interventions
Intranasal fentanyl, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Not applicable Interventional

The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy

NCT02489617
View directory record Official record
Conditions
Flat Epithelia Atypia, Intraductal Papilloma Without Atypia
Interventions
Pathologic evaluation of excised tissue
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 23, 2026, 8:25 AM EDT
Recruiting Phase 2 Interventional

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
Interventions
Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers

NCT00806806
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
SKY0402, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2010 · Synced Oct 23, 2026, 8:25 AM EDT
Terminated No phase listed Observational

Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects

NCT01018927
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Administering three additional MRI images
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 23, 2026, 8:25 AM EDT
Terminated Phase 2 Interventional Results available

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

NCT01369875
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, Tumor Infiltrating Lymphocytes
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of UGBRS Block and Local Infiltration

NCT02352519
View directory record Official record
Conditions
Appendicitis
Interventions
UGBRSB, Local Infiltration
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 23, 2026, 8:25 AM EDT
Terminated Not applicable Interventional

Oxandrolone Rotator Cuff Trial

NCT03091075
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Oxandrolone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
40 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 8:25 AM EDT
Recruiting Phase 1 Interventional

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

NCT05607095
View directory record Official record
Conditions
Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
Interventions
Lifileucel (LN-144/LN-145)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Not applicable Interventional

Local Infiltration Analgesia Vs. Interscalene Block in Total Shoulder Arthorplasty

NCT04415931
View directory record Official record
Conditions
Shoulder Osteoarthritis, Cuff Tear Arthropathy, Massive Rotator Cuff Tear
Interventions
Local infiltration analgesia, Interscalene block
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 23, 2026, 8:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
IOV-4001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 8:25 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

ENDOblock: Bilateral Superficial Cervical Blocks With Local Wound Infiltration in Thyroid Surgery

NCT05805423
View directory record Official record
Conditions
Post Operative Pain, Nausea and Vomiting, Postoperative, Opioid Use
Interventions
bilateral superficial cervical plexus blocks and local wound infiltration, placebo injection and local wound infiltration
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Phase 1 Interventional

Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation

NCT01445132
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Allogeneic Cell Therapy w/ Tumor-derived Lypho
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 23, 2026, 8:25 AM EDT
Enrolling by invitation Phase 4 Interventional

Intra-Articular Catheter Total Knee Arthroplasty

NCT06580899
View directory record Official record
Conditions
Continuous Local Infiltration Analgesia, Intra-articular Catheter, Total Knee Arthroplasty
Interventions
Intra-articular catheter, Routine Standard of Care Treatment
Device · Other
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

TAP Block With Plain Bupivacaine Versus Wound Infiltration With Exparel for Postoperative Pain Management

NCT02074709
View directory record Official record
Conditions
Postoperative Pain
Interventions
Plain bupivacaine, Liposomal bupivacaine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 23, 2026, 8:25 AM EDT
Withdrawn Not applicable Interventional

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

NCT02944357
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy, Tumor Cell-Derived Vaccine Therapy
Drug · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 23, 2026, 8:25 AM EDT
Terminated Phase 3 Interventional

ssTAP vs TAP Catheters in TAH

NCT02525900
View directory record Official record
Conditions
Postoperative Pain
Interventions
Wound Infiltration, TAP Blocks, TAP Catheters
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 23, 2026, 8:25 AM EDT
Completed Phase 1 Interventional

Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer

NCT00749437
View directory record Official record
Conditions
Breast Cancer
Interventions
3-dimensional conformal accelerated partial breast irradiation
Radiation
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
45 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 23, 2026, 8:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972
View directory record Official record
Conditions
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 8:25 AM EDT
Withdrawn Phase 1Phase 2 Interventional

CISH Inactivated TILs in the Treatment of NSCLC

NCT05566223
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions
Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 8:25 AM EDT